Ace Therapeutics, a preclinical contract research organization specializing in analgesic drug research, has announced its comprehensive end-to-end solutions for advancing pain therapeutic development. The platform features diverse validated in vivo pain models for drug testing and a complete suite of preclinical research capabilities for pharmaceutical and biotechnology customers worldwide.
Covering every stage from early target discovery and mechanism verification through pharmacological validation and safety assessment, Ace Therapeutics addresses the complex demands of modern pain drug research. The company builds integrated in vitro and in vivo research platforms tailored to study various physiological pain mechanisms, evaluate compound efficacy, and conduct safety profiling for novel analgesic candidates.
A core strength of Ace Therapeutics lies in its extensive portfolio of standardized and customized in vivo pain models for drug testing, which span nearly all mainstream pain classifications. These validated animal models include migraine models established via trigeminal ganglion electrical stimulation, nitroglycerin induction, and other approaches, as well as multiple neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.
To complement its in vivo systems, Ace Therapeutics has developed systematic preclinical pain assessment services, including mechanical pain, thermal pain, chemical pain, cold pain, and electrical stimulation pain assessments using well-established testing methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. Meanwhile, the in vitro neuropathic pain model development services leverage dorsal root ganglion (DRG) cells, iPSC-derived sensory neurons, and various co-culture systems to explore pain-related cellular mechanisms, further enhancing the translational value of preclinical research.
Beyond model construction and efficacy testing, Ace Therapeutics' preclinical analgesic drug development services extend to target-based and modality-based drug discovery. These services support research targeting G-protein coupled receptors, cytokine networks, and various ion channels, delivering professional solutions for small-molecule analgesics, biologics including antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. It also offers mechanism-driven research covering peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
The full-service pipeline of Ace Therapeutics also includes target validation, in vitro screening, in vivo pharmacology research, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection for analgesic drugs. For special research needs, Ace Therapeutics can also design customized pain models and testing assays according to unique drug mechanisms and research objectives.
This announcement is significant for the pharmaceutical industry as it provides a one-stop solution that can streamline the development of new analgesic drugs, potentially reducing the time and cost associated with bringing new pain medications to market. By offering a comprehensive platform with validated models and expert services, Ace Therapeutics aims to support the development of safer and more effective treatments for pain, addressing a major unmet medical need worldwide.
